ME3738: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 15894642 |
| SCHEMBL ID | 1982238 |
| MeSH ID | M0454055 |
| Synonym |
|---|
| me3738 |
| SCHEMBL1982238 |
| me-3738 |
| 186415-82-7 |
| 22beta-methoxyolean-12-ene-3beta,24(4beta)-diol |
| olean-12-ene-3,23-diol, 22-methoxy-, (3beta,4beta,22beta)- |
| sq4ra6v9gd , |
| (3beta,4beta,22beta)-22-methoxyolean-12-ene-3,23-diol |
| unii-sq4ra6v9gd |
| (3s,4s,4ar,6ar,6bs,8ar,9r,12as,14ar,14br)-4-(hydroxymethyl)-9-methoxy-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-ol |
| 22.beta.-methoxyolean-12-ene-3.beta.,24(4.beta.)-diol |
| (3.beta.,4.beta.,22.beta.)-22-methoxyolean-12-ene-3,23-diol |
| olean-12-ene-3,23-diol, 22-methoxy-, (3.beta.,4.beta.,22.beta.)- |
| FS-7228 |
ME3738 is a new compound that attenuates liver disease in several models of acute and chronic liver inflammation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "ME3738 is a new compound that attenuates liver disease in several models of acute and chronic liver inflammation. " | ( ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism. Heinrich, PC; Klein, C; Manns, MP; Streetz, KL; Trautwein, C; Wüstefeld, T, 2003) | 3.2 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "ME3738 is thought to inhibit replication of hepatitis C virus (HCV) by enhancing interferon (IFN)-β production, as determined using the HCV full-length binary expression system." | ( ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. Abe, H; Asai, K; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kawaoka, T; Maekawa, T; Matsuhira, T; Mitsui, F; Murakami, S; Ochi, H; Takahashi, S; Tateno, C; Tsuge, M; Yamashita, N; Yoshizato, K, 2011) | 2.53 |
ME3738-treatment, however, had no clear influence on the hydroxysteroid sulfotransferase 2a protein level. ME3738 treatment in male mice increased gene expression of alpha1-acid glycoprotein subtypes and serum amyloid A 2 genes.
| Excerpt | Reference | Relevance |
|---|---|---|
| "ME3738 treatment in male mice increased gene expression of alpha1-acid glycoprotein subtypes and serum amyloid A 2 genes, and plasma concentration of serum amyloid A." | ( Protective effects of alpha1-acid glycoprotein and serum amyloid A on concanavalin A-induced liver failure via interleukin-6 induction by ME3738. Imai, M; Kawamura, Y; Kurosawa, T; Kuzuhara, H; Nakano, Y; Nishiyama, S; Yamashita, N, 2006) | 1.26 |
| "ME3738-treatment, however, had no clear influence on the hydroxysteroid sulfotransferase 2a protein level and LCA 6alpha-, 6beta- and 7alpha-hydroxylase activities, but increased biliary cholesterol output." | ( ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Gonzalez, FJ; Kurosawa, T; Miyata, M; Nomoto, M; Shibasaki, S; Shimada, M; Shindo, Y; Yamazoe, Y; Yoshinari, K, 2007) | 2.5 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||